Global contract pharmaceutical manufacturing market is estimated to be valued at USD 232.28 Bn in 2025, and is expected to exhibit a CAGR of 9.9% during the forecast period (2025-2032). The global contract pharmaceutical manufacturing market has been witnessing steady growth over the past few years. Contract pharmaceutical manufacturing refers to the outsourcing of certain pharmaceutical processes such as manufacturing, packaging, and testing of pharmaceutical drugs to a third party company known as contract manufacturing organizations (CMOs). The growing need to reduce manufacturing costs and focus on core competencies are some of the key factors driving pharmaceutical companies to outsource their production requirements to CMOs. In addition, continued patent cliff losses, rising demand for generic drugs, and increasing outsourcing of drug development and commercialization activities are further expected to support the growth of the global contract pharmaceutical manufacturing market in the coming years.
Market Dynamics:
The global contract pharmaceutical manufacturing market growth is driven by rising incidence of cardiovascular diseases and increasing elderly population base globally who are at high risk of arrhythmias. According to the data by World Health Organization, cardiovascular diseases are the leading cause of deaths worldwide with over 17 million lives lost each year due to heart attacks and strokes. Moreover, technological innovations with focus on miniaturization and battery longevity have expanded indications for pacemaker implants. However, high costs associated with pacemaker procedures and risk of device complications such as lead defects and infections can hamper the market growth.
Key Features of the Study:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook